Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whichever occurs first. Approximatively 65 patients with aggressive large B-cell lymphoma (LBCL) (including diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), any transformed follicular or marginal zone lymphoma, high-grade B-cell lymphoma (HGBL)) will be enrolled in the study. The durati

Trial Details

NCT ID
NCT06271057
Phase
PHASE2
Sponsor
The Lymphoma Academic Research Organisation
Status
RECRUITING
Cancer Type
Marginal Zone Lymphoma Lymphoma
Interventions
  • golcadomide
Locations (sample)
  • Créteil, France|48.79266,2.46569
  • Dijon, France|47.31344,5.01391
  • La Tronche, France|45.20507,5.74629
  • Lille, France|50.63391,3.05512
  • Marseille, France|43.29695,5.38107

Key Eligibility Criteria

  • Patient who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures being conducted
  • Adults patients (≥ 18-year-old at the time of signing the informed consent form; no upper age limit)
  • Eligible for any commercialized market authorized anti-CD19 CAR T-cells
  • Performance Status 0, 1, or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Marginal Zone Lymphoma Lymphoma Trials on Trialify →